SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Charles Darwin Synthetic CCD

PatientCharles Darwin
Date of birth1986-02-12
IdentifiersMRN HR-NI003-SYN; SSN (made up) 000-03-2967
Document date2026-11-01
AuthorBernard Ashworth, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Evaluation of recurrent vomiting episodes: history, symptom diary, Rome IV criteria, red flags, cannabis and substance history, anxiety and mood screens, laboratory tests, ECG, and orders for small-bowel imaging and upper endoscopy. Concerns: For more than a year he has had episodes of nausea and repeated vomiting every one to three weeks, each lasting about 12 to 36 hours, that stop his work; this winter they came almost every week; Each episode begins with nausea, sweating, trembling hands, a racing heart, and a swimming head; between episodes he has troublesome wind and tires easily, but does not vomit; He worries about being taken ill in company and has begun to avoid gatherings and travel. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Amitriptyline 25 mg oral tablet, one tablet at bedtimeOne tablet by mouth at bedtimeOral route2026-04-14 to 2026-04-28completedS
Amitriptyline 50 mg oral tablet, one tablet at bedtimeOne tablet by mouth at bedtimeOral route2026-04-28 to 2026-05-12completedS
Amitriptyline 75 mg oral tablet, one tablet at bedtimeOne tablet by mouth at bedtimeOral route2026-05-12activeS
Sumatriptan 20 mg nasal spray, one spray at the first sign of an episodeOne spray in one nostril at the start of the prodrome; may repeat once after 2 hours; no more than 2 sprays a day or 6 a weekNasal route2026-04-14activeS
Ondansetron 8 mg orally disintegrating tablet at the first sign of an episodeDissolve one tablet on the tongue at the start of the prodrome, then every 8 hours as needed during an episodeOral route2026-04-14activeS

Procedures

ProcedureDatesStatusEvidence
CT enterography (CT of the small bowel with oral and intravenous contrast): normal small and large bowel, no obstruction, malrotation, stricture, or wall thickening; normal liver, gallbladder, pancreas, and kidneys2026-03-17 to 2026-03-17completedS
Upper endoscopy (esophagogastroduodenoscopy) with duodenal biopsies: normal esophagus, stomach, and duodenum; no ulcer, obstruction, or retained food; duodenal biopsies normal2026-03-31 to 2026-03-31completedS

Immunizations

DateVaccineStatusEvidence
2025-10-14Influenza vaccine, 2025-2026 seasoncompletedS
2019-06-11Tetanus, diphtheria, and acellular pertussis (Tdap) boostercompletedS
2026-07-21Hepatitis B vaccine (adjuvanted, two-dose series), dose 1completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
December 1831Palpitations and pain about the heart while waiting to sail on the Beagle; no doctor consultedD (CLM-0003)
September 1837Palpitations, treated with rest in the country on his doctors' adviceD (CLM-0004)
June 1840Periodical vomiting, first mentioned in a letter; cause not recorded in the cited sourceD (CLM-0005)
February 1849A winter of dreadful vomiting every week, with trembling hands and a swimming head, and incessant vomiting described in a letter; cause not recorded in the cited sourceD (CLM-0006)

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Health Concerns

ConcernStatusEvidence
For more than a year he has had episodes of nausea and repeated vomiting every one to three weeks, each lasting about 12 to 36 hours, that stop his work; this winter they came almost every weekactiveS
Each episode begins with nausea, sweating, trembling hands, a racing heart, and a swimming head; between episodes he has troublesome wind and tires easily, but does not vomitactiveS
He worries about being taken ill in company and has begun to avoid gatherings and travelactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 14.6 on 2026-03-03; Leukocytes [#/volume] in Blood by Automated count 6.4 on 2026-03-03; Platelets [#/volume] in Blood by Automated count 251 on 2026-03-03; Sodium [Moles/volume] in Serum or Plasma 140 on 2026-03-03; Potassium [Moles/volume] in Serum or Plasma 4.1 on 2026-03-03; Chloride [Moles/volume] in Serum or Plasma 103 on 2026-03-03; Carbon dioxide, total [Moles/volume] in Serum or Plasma 25 on 2026-03-03; Creatinine [Mass/volume] in Serum or Plasma 0.94 on 2026-03-03; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 104 on 2026-03-03; Glucose [Mass/volume] in Serum or Plasma 88 on 2026-03-03; Calcium [Mass/volume] in Serum or Plasma 9.5 on 2026-03-03; Albumin [Mass/volume] in Serum or Plasma 4.4 on 2026-03-03; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 21 on 2026-03-03; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 19 on 2026-03-03; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 68 on 2026-03-03; Bilirubin.total [Mass/volume] in Serum or Plasma 0.7 on 2026-03-03; Lipase [Enzymatic activity/volume] in Serum or Plasma 32 on 2026-03-03; Thyrotropin [Units/volume] in Serum or Plasma 1.6 on 2026-03-03; Cortisol [Mass/volume] in Serum or Plasma 14.2 on 2026-03-03; Tissue transglutaminase IgA Ab [Units/volume] in Serum 1.2 on 2026-03-03; IgA [Mass/volume] in Serum or Plasma 210 on 2026-03-03; Q-T interval corrected 436 on 2026-06-09; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 5 on 2026-09-08; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-09-08; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-07-21; Total score [AUDIT-C] 2 on 2026-07-21; Cholesterol [Mass/volume] in Serum or Plasma 178 on 2026-07-21; Cholesterol in HDL [Mass/volume] in Serum or Plasma 58 on 2026-07-21; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 102 on 2026-07-21; Triglyceride [Mass/volume] in Serum or Plasma 90 on 2026-07-21 [S]

Strengths and supports: Supports: a settled household, absorbing scientific work, daily walks, and a habit of keeping careful notes that suits a symptom diary [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Cyclic vomiting syndrome, moderate to severe, meeting Rome IV criteria after a normal work-up; provisional clinical diagnosisactiveprovisional R11.15S — Synthetic provisional diagnosis at the gastroenterology consultation, anchored to his documented episodic vomiting. It is clinical, with no confirmatory test, and does not confirm any historical theory.
Recurrent episodes of nausea and vomiting over more than a year, with prodromal trembling, palpitations, and dizziness, and flatulence and fatigue between episodes; cause under evaluationresolvedconfirmed R11.2S — Synthetic presenting concern at the index visit, superseded by the provisional diagnosis at the six-week visit; the episodic vomiting is documented (D).
Common cold, without a vomiting episode; resolvedresolvedconfirmed J00S — Synthetic intercurrent illness at an unscheduled visit; chosen because infection is a common trigger of cyclic vomiting and because cold medicines interact with amitriptyline. It does not echo a documented illness.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-03-03Hemoglobin [Mass/volume] in Blood14.6g/dL13.2-16.6 g/dLNormalS
2026-03-03Leukocytes [#/volume] in Blood by Automated count6.410*3/uL3.4-9.6 10*3/uLNormalS
2026-03-03Platelets [#/volume] in Blood by Automated count25110*3/uL135-317 10*3/uLNormalS
2026-03-03Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-03-03Potassium [Moles/volume] in Serum or Plasma4.1mmol/L3.5-5.1 mmol/LNormalS
2026-03-03Chloride [Moles/volume] in Serum or Plasma103mmol/L98-107 mmol/LNormalS
2026-03-03Carbon dioxide, total [Moles/volume] in Serum or Plasma25mmol/L22-29 mmol/LNormalS
2026-03-03Creatinine [Mass/volume] in Serum or Plasma0.94mg/dL0.74-1.35 mg/dLNormalS
2026-03-03Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M104mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-03-03Glucose [Mass/volume] in Serum or Plasma88mg/dL70-99 mg/dLNormalS
2026-03-03Calcium [Mass/volume] in Serum or Plasma9.5mg/dL8.6-10.3 mg/dLNormalS
2026-03-03Albumin [Mass/volume] in Serum or Plasma4.4g/dL3.5-5 g/dLNormalS
2026-03-03Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma21U/L7-55 U/LNormalS
2026-03-03Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma19U/L8-48 U/LNormalS
2026-03-03Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma68U/L40-129 U/LNormalS
2026-03-03Bilirubin.total [Mass/volume] in Serum or Plasma0.7mg/dL0.1-1.2 mg/dLNormalS
2026-03-03Lipase [Enzymatic activity/volume] in Serum or Plasma32U/L13-60 U/LNormalS
2026-03-03Thyrotropin [Units/volume] in Serum or Plasma1.6m[IU]/L0.45-4.5 mIU/LNormalS
2026-03-03Cortisol [Mass/volume] in Serum or Plasma14.2ug/dL6.2-19.4 ug/dLNormalS
2026-03-03Tissue transglutaminase IgA Ab [Units/volume] in Serum1.2U/mL<=3.9 U/mLNormalS
2026-03-03IgA [Mass/volume] in Serum or Plasma210mg/dL70-400 mg/dLNormalS
2026-03-03Q-T interval corrected412ms<=450 msNormalS
2026-06-09Q-T interval corrected436ms<=450 msNormalS
2026-03-03Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]8{score}S
2026-03-03Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
2026-06-09Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]6{score}S
2026-06-09Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
2026-09-08Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]5{score}S
2026-09-08Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
2026-07-21Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2026-07-21Total score [AUDIT-C]2{score}S
2026-07-21Cholesterol [Mass/volume] in Serum or Plasma178mg/dL<=200 mg/dLNormalS
2026-07-21Cholesterol in HDL [Mass/volume] in Serum or Plasma58mg/dL>=40 mg/dLNormalS
2026-07-21Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation102mg/dL<=129 mg/dLNormalS
2026-07-21Triglyceride [Mass/volume] in Serum or Plasma90mg/dL<=149 mg/dLNormalS

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-03-03Body height183cmS
2026-03-03Body weight71.6kgS
2026-03-03Body mass index (BMI) [Ratio]21.4kg/m2S
2026-03-03Systolic blood pressure118mm[Hg]S
2026-03-03Diastolic blood pressure74mm[Hg]S
2026-03-03Heart rate78/minS
2026-03-03Respiratory rate14/minS
2026-03-03Body temperature36.6CelS
2026-03-03Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-04-14Body height183cmS
2026-04-14Body weight71.4kgS
2026-04-14Body mass index (BMI) [Ratio]21.3kg/m2S
2026-04-14Systolic blood pressure116mm[Hg]S
2026-04-14Diastolic blood pressure72mm[Hg]S
2026-04-14Heart rate76/minS
2026-04-14Respiratory rate14/minS
2026-04-14Body temperature36.7CelS
2026-04-14Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-06-09Body height183cmS
2026-06-09Body weight72.4kgS
2026-06-09Body mass index (BMI) [Ratio]21.6kg/m2S
2026-06-09Systolic blood pressure118mm[Hg]S
2026-06-09Diastolic blood pressure74mm[Hg]S
2026-06-09Heart rate72/minS
2026-06-09Respiratory rate14/minS
2026-06-09Body temperature36.6CelS
2026-06-09Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-09-08Body height183cmS
2026-09-08Body weight72.9kgS
2026-09-08Body mass index (BMI) [Ratio]21.8kg/m2S
2026-09-08Systolic blood pressure116mm[Hg]S
2026-09-08Diastolic blood pressure72mm[Hg]S
2026-09-08Heart rate70/minS
2026-09-08Respiratory rate14/minS
2026-09-08Body temperature36.6CelS
2026-09-08Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-05-19Body height183cmS
2026-05-19Body weight72.1kgS
2026-05-19Body mass index (BMI) [Ratio]21.5kg/m2S
2026-05-19Systolic blood pressure118mm[Hg]S
2026-05-19Diastolic blood pressure72mm[Hg]S
2026-05-19Heart rate84/minS
2026-05-19Respiratory rate16/minS
2026-05-19Body temperature37.8CelS
2026-05-19Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-07-21Body height183cmS
2026-07-21Body weight72.6kgS
2026-07-21Body mass index (BMI) [Ratio]21.7kg/m2S
2026-07-21Systolic blood pressure116mm[Hg]S
2026-07-21Diastolic blood pressure72mm[Hg]S
2026-07-21Heart rate70/minS
2026-07-21Respiratory rate14/minS
2026-07-21Body temperature36.6CelS
2026-07-21Oxygen saturation in Arterial blood by Pulse oximetry99%S

Encounters

DatePurposeStatusProvenance
2026-03-03Evaluation of recurrent vomiting episodes: history, symptom diary, Rome IV criteria, red flags, cannabis and substance history, anxiety and mood screens, laboratory tests, ECG, and orders for small-bowel imaging and upper endoscopyfinishedS
2026-04-14Six-week follow-up: results, gastroenterology consultation, provisional diagnosis, prophylaxis, and abortive planfinishedS
2026-06-09Three-month review: amitriptyline at target dose, ECG, episode diary, and anxiety screenfinishedS
2026-09-08Six-month review of response to prophylaxisfinishedS
2026-05-19Same-day sick visit for a head coldfinishedS
2026-07-21Preventive health visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Work-up between episodes: blood count, metabolic and liver panels, lipase, urinalysis, TSH, morning cortisol, celiac serology, a baseline ECG, CT enterography, and upper endoscopycompletedGL-ANMS-CVS-2019S
Gastroenterology consultation to confirm the diagnosis and advise on prophylaxis, abortive treatment, and an emergency plancompletedGL-ANMS-CVS-2019S
Symptom diary: date, prodrome, length and severity of each episode, triggers, medicines taken, and emergency visitscompletedGL-ANMS-CVS-2019S
Amitriptyline prophylaxis at bedtime: 25 mg, raised by 25 mg every two weeks to 75 mg (about 1 mg/kg), with an ECG at baseline, at about 50 mg, and at the target dose; judge the response after three months at target and continue for at least a year if it helpscompletedGL-ANMS-CVS-2019S
Abortive plan at the first sign of the prodrome: sumatriptan 20 mg nasal spray with ondansetron 8 mg dissolving tablet, a dark quiet room, and small sips of fluid; an individualized emergency department letter for episodes that do not settlecompletedGL-ANMS-CVS-2019S
Trigger management: regular meals and sleep, planning around travel and social events, early treatment of infections, and continued avoidance of cannabiscompletedGL-ANMS-CVS-2019S
Anxiety and mood: GAD-7 and PHQ-9 at the first visit and every three months; relaxation breathing, with cognitive behavioral therapy offered if symptoms persistcompletedGL-ANMS-CVS-2019, GL-USPSTF-ANX-2023S

Goals

GoalTargetStatusOutcomeProvenance
Complete the work-up between episodes (blood and urine tests, ECG, CT enterography, and upper endoscopy) before the six-week visit2026-04-14completedAll tests normal; Rome IV criteria met; provisional diagnosis of cyclic vomiting syndrome at the consultationS
At least half as many episodes after three months at the target dose of prophylaxis2026-09-08completedAbout two episodes a month before treatment; one brief episode, aborted at the prodrome, in the three months before the six-month reviewS
Carry the abortive medicines and the emergency department letter, and use them at the prodrome2026-06-09completedThe one episode since starting treatment was treated at the prodrome and settled in about ten hours without an emergency visit; letter carriedS
QTc below 450 ms at the target amitriptyline dose2026-06-09completedQTc 436 ms on 75 mgS
Practice relaxation breathing most days and lower the GAD-7 score by the six-month review2026-09-08completedDaily breathing practice; GAD-7 from 8 to 5S

Functional Status

Mental Status